{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:17:03Z","timestamp":1775899023744,"version":"3.50.1"},"reference-count":31,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2022,3,31]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Anti-interleukin (IL)-5\/IL-5 receptor \u03b1 (IL-5Ra) therapy has been shown to reduce maintenance oral corticosteroid (OCS) dose in severe eosinophilic asthma. However, the effect on cumulative OCS exposure is currently unknown. Neither is it known how prior OCS exposure affects response to anti-IL-5\/5Ra treatment. We aimed primarily to compare the cumulative OCS exposure over a 2-year period before and after anti-IL-5\/5Ra initiation, and secondarily to investigate whether duration and cumulative OCS exposure prior to anti-IL-5\/5Ra influence the ability to discontinue OCS within 2\u2005years of anti-IL-5\/5Ra therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This real-world nationwide observational registry-based study evaluated all dispensed OCS from 389 adults with severe eosinophilic asthma included in the Dutch Severe Asthma Registry (RAPSODI) 2\u2005years before and 2\u2005years after initiating anti-IL-5\/5Ra. The Wilcoxon signed-rank test and multivariable regression analyses were used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median (interquartile range) cumulative OCS exposure in the 2\u2005years before and after anti-IL-5\/5Ra initiation decreased from 2.715 (1.150\u20135.539) to 1.050 (0.300\u20133.640)\u2005g (p&lt;0.001). 52% of patients were able to discontinue OCS within 2\u2005years after anti-IL-5\/5Ra therapy, which was independently predicted by lower and shorter prior OCS exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This real-world study showed that anti-IL-5\/5Ra therapy leads to a significant reduction in cumulative OCS exposure over a 2-year period. Patients with lower and shorter OCS exposure were more likely to completely eliminate OCS. Since cumulative exposure increased progressively prior to anti-IL-5\/5Ra initiation, our data suggest that early intervention leads to a better long-term prognosis in patients with severe eosinophilic asthma.<\/jats:p><\/jats:sec>","DOI":"10.1183\/13993003.02983-2021","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T16:24:49Z","timestamp":1653323089000},"page":"2102983","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Cumulative corticosteroid-sparing effect of anti-interleukin-5\/5Ra in eosinophilic asthma"],"prefix":"10.1183","volume":"60","author":[{"given":"Johannes A.","family":"Kroes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sybrand W.J.","family":"Zielhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"De Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8995-3817","authenticated-orcid":false,"given":"Simone","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob K.","family":"Sont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander W.","family":"Zielhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric N.","family":"Van Roon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth H.","family":"Bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneke","family":"Ten Brinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"2024102102582684000_60.5.2102983.1","unstructured":"Global Initiative for Asthma (GINA) . Difficult-to-treat & Severe Asthma in Adolescent and Adult Patients. Diagnosis and Management. 2021. www.ginasthma.org\/wp-content\/uploads\/2021\/08\/SA-Pocket-guide-v3.0-SCREEN-WMS.pdf Date last accessed: 13 September 2021."},{"key":"2024102102582684000_60.5.2102983.2","doi-asserted-by":"crossref","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2019","journal-title":"Eur Respir J"},{"key":"2024102102582684000_60.5.2102983.3","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"2024102102582684000_60.5.2102983.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.99.13101599"},{"key":"2024102102582684000_60.5.2102983.5","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12954"},{"key":"2024102102582684000_60.5.2102983.6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01163-2019"},{"key":"2024102102582684000_60.5.2102983.7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102102582684000_60.5.2102983.8","doi-asserted-by":"publisher","DOI":"10.1111\/all.13556"},{"key":"2024102102582684000_60.5.2102983.9","first-page":"833","article-title":"Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma","volume":"22","author":"Dalal","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"2024102102582684000_60.5.2102983.10","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.56.4.279"},{"key":"2024102102582684000_60.5.2102983.11","doi-asserted-by":"publisher","DOI":"10.1177\/1753465815581279"},{"key":"2024102102582684000_60.5.2102983.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2024102102582684000_60.5.2102983.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"2024102102582684000_60.5.2102983.14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2024102102582684000_60.5.2102983.15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jaip.2019.09.036","article-title":"Efficacy of intravenous reslizumab in oral corticosteroid-dependent asthma","volume":"8","author":"Nair","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102102582684000_60.5.2102983.16","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"2024102102582684000_60.5.2102983.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"2024102102582684000_60.5.2102983.18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024102102582684000_60.5.2102983.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00936-2018"},{"key":"2024102102582684000_60.5.2102983.20","unstructured":"NVALT . Aanvullende behandelingen bij ernstig astma. [Additional treatments in severe asthma.] 2020. https:\/\/richtlijnendatabase.nl\/richtlijn\/diagnostiek_en_behandeling_van_ernstig_astma\/aanvullende_behandelingen_bij_ernstig_astma.html Date last accessed: 8 January 2022."},{"key":"2024102102582684000_60.5.2102983.21","unstructured":"The National Exchange Point . How does it work? 2021. www.volgjezorg.nl\/en\/lsp. Date last accessed: 10 October 2021."},{"key":"2024102102582684000_60.5.2102983.22","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.jaip.2021.01.028","article-title":"Mepolizumab and oral corticosteroid stewardship: data from the Australian Mepolizumab Registry","volume":"9","author":"Thomas","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102102582684000_60.5.2102983.23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2147\/JAA.S275944","article-title":"Real-world reductions in oral corticosteroid use in the USA following mepolizumab therapy for severe asthma","volume":"13","author":"Silver","year":"2020","journal-title":"J Asthma Allergy"},{"key":"2024102102582684000_60.5.2102983.24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4137\/JCD.S10818","article-title":"Eosinophil apoptosis and clearance in asthma","volume":"6","author":"Walsh","year":"2013","journal-title":"J Cell Death"},{"key":"2024102102582684000_60.5.2102983.25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11882-019-0868-0","article-title":"Charcot\u2013Leyden crystals in eosinophilic inflammation: active cytolysis leads to crystal formation","volume":"19","author":"Ueki","year":"2019","journal-title":"Curr Allergy Asthma Rep"},{"key":"2024102102582684000_60.5.2102983.26","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.iac.2018.06.003","article-title":"Airway eosinophilopoietic and autoimmune mechanisms of eosinophilia in severe asthma","volume":"38","author":"Bhalla","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"2024102102582684000_60.5.2102983.27","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaip.2017.05.032","article-title":"Baseline features of the Severe Asthma Research Program (SARP III) cohort: differences with age","volume":"6","author":"Teague","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102102582684000_60.5.2102983.28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00779-2015"},{"key":"2024102102582684000_60.5.2102983.29","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jaip.2020.12.013","article-title":"Optimizing omalizumab dosing in severe asthma \u2013 the exploration of therapeutic drug monitoring","volume":"9","author":"Kroes","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102102582684000_60.5.2102983.30","doi-asserted-by":"publisher","DOI":"10.1038\/nri3786"},{"key":"2024102102582684000_60.5.2102983.31","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02273-2019"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02983-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:07:02Z","timestamp":1740380822000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02983-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,11,3]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1183\/13993003.02983-2021"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02983-2021","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]}}}